Promising arm 1 results from MiST trial to be presented at ASCO meeting

The University of Leicester and University Hospitals of Leicester NHS Trust clinical trial, funded by the British Lung Foundation and the Victor Dahdaleh Foundation, is investigating personalised treatments for mesothelioma.

Initial results from arm one of the Mesothelioma Stratified Therapy (MiST) trial, led by Professor Anne Thomas and Professor Dean Fennell, showed a disease control rate (DCR) of 57.7% (95% CI, 36.9 - 76.7) at 12 weeks. This demonstrates a promising efficacy and with manageable toxicity from treatment.

Rucaparib is a PARP inhibitor currently used to treat ovarian, fallopian and peritoneal cancers. The use of rucaparib as a treatment in arm one of the MiST trial follows on from earlier pre-clinical research at Leicester funded by the British Lung Foundation. These recent results confirm activity of PARP inhibitors in mesothelioma, therefore validating this earlier finding.

The MiST trial is the world’s first molecularly stratified trial that is designed to identify first signals of treatments working well and to support development of new, promising medicines for mesothelioma.

MiST arms two and four are ongoing in Leicester and Newcastle hospitals, and arm three is due to open imminently. It was recently confirmed that further funding has been leveraged from the pharmaceutical industry to enable a new arm of the trial – arm 5. The funding is accompanied by free use of the treatment drugs, up to the value of £2 million.

The full abstract is on the ASCO website>

more information on the trial can be found on Clinical

                                                                                  MisT logo